Name : Biotinylated Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer Protein
Product Source :
Recombinant Biotinylated Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and HMTEVVRHC peptide.[Accession | A0A140T913(HLA-A*02:01)&P61769(B2M)&HMTEVVRHC]
Molecular Weight :
The protein has a predicted MW of 50.5 kDa. Due to glycosylation, the protein migrates to 55-60 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22 μm filtered solution in 20mM PB, 500mM NaCl (pH 8.0). Normally 8% trehalose / 8% mannitol is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Biotinylated Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Biotinylated Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer was greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Anti-HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Antibody, hFc Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer, His Tag with the EC50 of 0.25μg/ml determined by ELISA.
Background :
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.
Synonyms :
MHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53
References & Citations :
(1) Kanapathipillai M. Treating p53 Mutant Aggregation-Associated Cancer. Cancers (Basel). 2018 May 23;10(6):154. doi: 10.3390/cancers10060154. PMID: 29789497; PMCID: PMC6025594.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
Beta-NGF Protein
FGFR-4 Protein
Popular categories:
TIE Receptors
ITIH5